EXOC6

Summary

EXOC6 (exocyst complex component 6, HGNC:23196) is a protein-coding gene on chromosome 10q23.33, encoding Exocyst complex component 6 (Q8TAG9). Component of the exocyst complex involved in the docking of exocytic vesicles with fusion sites on the plasma membrane.

The protein encoded by this gene is highly similar to the Saccharomyces cerevisiae SEC15 gene product, which is essential for vesicular traffic from the Golgi apparatus to the cell surface in yeast. It is one of the components of a multiprotein complex required for exocytosis. The 5’ portion of this gene and two neighboring cytochrome p450 genes are included in a deletion that results in an autosomal-dominant form of nonsyndromic optic nerve aplasia (ONA). Alternative splicing and the use of alternative promoters results in multiple transcript variants. A paralogous gene encoding a similar protein is present on chromosome 2.

Source: NCBI Gene 54536 — RefSeq curated summary.

At a glance

• GWAS associations: 18
• Clinical variants (ClinVar): 115 total
• MANE Select transcript: NM_019053

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23196
Approved symbol	EXOC6
Name	exocyst complex component 6
Location	10q23.33
Locus type	gene with protein product
Status	Approved
Aliases	SEC15L, FLJ1125, DKFZp761I2124, MGC33397, Sec15, EXOC6A
Ensembl gene	ENSG00000138190
Ensembl biotype	protein_coding
OMIM	609672
Entrez	54536

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 7 protein_coding, 1 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000260762, ENST00000371543, ENST00000371552, ENST00000443748, ENST00000458552, ENST00000495132, ENST00000497262, ENST00000671701, ENST00000672817

RefSeq mRNA: 5 — MANE Select: NM_019053 NM_001013848, NM_001319194, NM_001319195, NM_001319200, NM_019053

CCDS: CCDS31247, CCDS7424, CCDS81487

Canonical transcript exons

ENST00000260762 — 22 exons

Exon	Start	End
ENSE00000932902	92997474	92997615
ENSE00001092299	92952273	92952382
ENSE00001092302	92954630	92954741
ENSE00001092305	92934310	92934430
ENSE00001092306	92955580	92955714
ENSE00001092308	92948274	92948379
ENSE00001092309	92974053	92974232
ENSE00001092311	92940727	92940824
ENSE00001092313	92935814	92935885
ENSE00001609010	92894930	92895020
ENSE00001646597	92915758	92915913
ENSE00001695079	92893349	92893520
ENSE00001711379	92928339	92928422
ENSE00001712164	92899599	92899644
ENSE00001765204	92909427	92909631
ENSE00001780826	92919982	92920050
ENSE00001791133	92894794	92894841
ENSE00001838377	93058223	93059490
ENSE00001951215	92848520	92848634
ENSE00002431663	92934144	92934190
ENSE00003560949	93056924	93057036
ENSE00003786631	93014194	93014267

Expression profiles

Bgee: expression breadth ubiquitous, 249 present calls, max score 95.18.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 16.8194 / max 315.7795, expressed in 1716 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
106264	12.7440	1671
106263	3.1419	1306
106256	0.4374	125
106253	0.2070	89
106254	0.1151	66
106259	0.0650	33
106255	0.0572	28
106258	0.0319	13
106257	0.0199	8

Top tissues by expression

257 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
deltoid	UBERON:0001476	95.18	gold quality
epithelial cell of pancreas	CL:0000083	94.86	gold quality
vastus lateralis	UBERON:0001379	94.12	gold quality
quadriceps femoris	UBERON:0001377	93.77	gold quality
middle temporal gyrus	UBERON:0002771	92.59	gold quality
tibialis anterior	UBERON:0001385	92.18	gold quality
adrenal tissue	UBERON:0018303	92.12	gold quality
buccal mucosa cell	CL:0002336	92.08	gold quality
skeletal muscle tissue	UBERON:0001134	91.90	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	91.68	gold quality
biceps brachii	UBERON:0001507	91.63	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	90.52	gold quality
muscle tissue	UBERON:0002385	90.17	gold quality
islet of Langerhans	UBERON:0000006	88.95	gold quality
cortical plate	UBERON:0005343	88.54	gold quality
skeletal muscle organ	UBERON:0014892	88.35	gold quality
placenta	UBERON:0001987	88.25	gold quality
hindlimb stylopod muscle	UBERON:0004252	87.32	gold quality
visceral pleura	UBERON:0002401	87.29	gold quality
muscle of leg	UBERON:0001383	87.14	gold quality
endothelial cell	CL:0000115	86.90	gold quality
gastrocnemius	UBERON:0001388	86.76	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	86.58	gold quality
Brodmann (1909) area 23	UBERON:0013554	86.50	gold quality
ventricular zone	UBERON:0003053	86.12	gold quality
blood	UBERON:0000178	86.04	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	85.63	gold quality
pigmented layer of retina	UBERON:0001782	85.55	gold quality
retina	UBERON:0000966	85.53	gold quality
embryo	UBERON:0000922	85.20	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-MTAB-7316	yes	35.12
E-GEOD-81608	yes	4.98
E-GEOD-81547	yes	4.59
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

89 targeting EXOC6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-548AZ-5P	99.83	69.94	3230
HSA-MIR-548T-5P	99.83	69.91	3220
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-4799-5P	99.82	70.60	2663

Literature-anchored findings (GeneRIF, showing 4)

• Sec15 has a role as an effector for the Rab11 GTPase in mammalian cells (PMID:15292201)
• The SEC15 protein plays a crucial role in integrating the signals between Sec4p and the components of the early-polarity-establishment machinery. (PMID:16478783)
• coordinated disruption of the Rab11/Sec15 exocyst by anthrax toxins may contribute to toxin-dependent barrier disruption and vascular dysfunction during B. anthracis infection (PMID:20944747)
• NDR2-mediated Rabin8 phosphorylation is crucial for ciliogenesis by triggering the switch in binding specificity of Rabin8 from PS to Sec15. (PMID:23435566)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	exoc6	ENSDARG00000020521
mus_musculus	Exoc6	ENSMUSG00000053799
rattus_norvegicus	Exoc6	ENSRNOG00000036601
drosophila_melanogaster	Sec15	FBGN0266674
caenorhabditis_elegans		WBGENE00016188

Paralogs (1): EXOC6B (ENSG00000144036)

Protein

Protein identifiers

Exocyst complex component 6 — Q8TAG9 (reviewed: Q8TAG9)

Alternative names: Exocyst complex component Sec15A, SEC15-like protein 1

All UniProt accessions (5): Q8TAG9, B1AP46, E7EW84, F2Z3K0, H0Y5J8

UniProt curated annotations — full annotation on UniProt →

Function. Component of the exocyst complex involved in the docking of exocytic vesicles with fusion sites on the plasma membrane. Together with RAB11A, RAB3IP, RAB8A, PARD3, PRKCI, ANXA2, CDC42 and DNMBP promotes transcytosis of PODXL to the apical membrane initiation sites (AMIS), apical surface formation and lumenogenesis.

Subunit / interactions. The exocyst complex is composed of EXOC1, EXOC2, EXOC3, EXOC4, EXOC5, EXOC6, EXOC7 and EXOC8. Interacts with CNTRL. Interacts with RAB11A in a GTP-dependent manner.

Subcellular location. Cytoplasm. Perinuclear region. Cell projection. Growth cone. Midbody. Midbody ring.

Similarity. Belongs to the SEC15 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8TAG9-1	1	yes
Q8TAG9-2	2

RefSeq proteins (5): NP_001013870, NP_001306123, NP_001306124, NP_001306129, NP_061926* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007225	EXOC6/Sec15	Family
IPR042044	EXOC6PINT-1/Sec15/Tip20_C_dom2	Homologous_superfamily
IPR042045	EXOC6/Sec15_C_dom1	Homologous_superfamily
IPR046361	EXOC6/Sec15_C	Domain
IPR048359	EXOC6_Sec15_N	Domain

Pfam: PF04091, PF20651

UniProt features (6 total): sequence variant 3, chain 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8TAG9-F1	82.02	0.42

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-1445148	Translocation of SLC2A4 (GLUT4) to the plasma membrane
R-HSA-264876	Insulin processing
R-HSA-5620916	VxPx cargo-targeting to cilium

MSigDB gene sets: 221 (showing top): WENDT_COHESIN_TARGETS_UP, GOBP_MITOTIC_CYTOKINESIS, RNGTGGGC_UNKNOWN, GOBP_VESICLE_LOCALIZATION, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, GOBP_VESICLE_TARGETING, GOBP_VESICLE_MEDIATED_TRANSPORT, TAL1ALPHAE47_01, REACTOME_MEMBRANE_TRAFFICKING, CAGCTG_AP4_Q5, YY1_Q6, GOBP_MEMBRANE_DOCKING

GO Biological Process (8): mitotic cytokinesis (GO:0000281), intracellular protein transport (GO:0006886), exocytosis (GO:0006887), Golgi to plasma membrane transport (GO:0006893), obsolete vesicle docking involved in exocytosis (GO:0006904), membrane fission (GO:0090148), obsolete vesicle tethering involved in exocytosis (GO:0090522), protein transport (GO:0015031)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (8): exocyst (GO:0000145), cytosol (GO:0005829), plasma membrane (GO:0005886), growth cone (GO:0030426), perinuclear region of cytoplasm (GO:0048471), Flemming body (GO:0090543), cytoplasm (GO:0005737), cell projection (GO:0042995)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Membrane Trafficking	1
Peptide hormone metabolism	1
Cargo trafficking to the periciliary membrane	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
intracellular protein localization	2
cytoplasm	2
mitotic cell cycle	1
cytoskeleton-dependent cytokinesis	1
mitotic cell cycle process	1
protein transport	1
intracellular transport	1
vesicle-mediated transport	1
secretion by cell	1
vesicle fusion to plasma membrane	1
post-Golgi vesicle-mediated transport	1
vesicle-mediated transport to the plasma membrane	1
membrane organization	1
transport	1
establishment of protein localization	1
binding	1
cell cortex	1
vesicle tethering complex	1
membrane	1
cell periphery	1
site of polarized growth	1
distal axon	1
midbody	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1392 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
EXOC6	EXOC2	Q96KP1	999
EXOC6	EXOC4	Q96A65	999
EXOC6	EXOC5	O00471	999
EXOC6	EXOC8	Q8IYI6	999
EXOC6	EXOC1	Q9NV70	999
EXOC6	EXOC7	Q9UPT5	999
EXOC6	EXOC3	O60645	998
EXOC6	RAB11A	P24410	998
EXOC6	FUT2	Q10981	959
EXOC6	RAB10	P61026	921
EXOC6	RAB8A	P24407	891
EXOC6	RAB3IP	Q96QF0	881
EXOC6	MYO5B	Q9ULV0	752
EXOC6	RABIF	P47224	714
EXOC6	HBD	P02042	713

IntAct

130 interactions, top by confidence:

A	B	Type	Score
EXOC6	EXOC5	psi-mi:“MI:0914”(association)	0.840
EXOC5	EXOC6	psi-mi:“MI:0915”(physical association)	0.840
EXOC6B	EXOC5	psi-mi:“MI:0914”(association)	0.790
EXOC3	EXOC5	psi-mi:“MI:0914”(association)	0.790
DSN1	NDC80	psi-mi:“MI:0914”(association)	0.790
EXOC1	EXOC5	psi-mi:“MI:0914”(association)	0.730
EXOC8	EXOC5	psi-mi:“MI:0914”(association)	0.730
SCN2B	EXOC5	psi-mi:“MI:0914”(association)	0.640
GYPA	TCAF2	psi-mi:“MI:0914”(association)	0.640
EXOC6	GLE1	psi-mi:“MI:0915”(physical association)	0.560
EXOC6	SPRED1	psi-mi:“MI:0915”(physical association)	0.560
APLNR	METTL15	psi-mi:“MI:0914”(association)	0.530
NPY2R	RTL8C	psi-mi:“MI:0914”(association)	0.530
DSN1	EXOC5	psi-mi:“MI:0914”(association)	0.530
FAM174A	BLTP3B	psi-mi:“MI:0914”(association)	0.530
CXCR4	TMEM120B	psi-mi:“MI:0914”(association)	0.530
MAS1	POTEF	psi-mi:“MI:0914”(association)	0.530
CD70	METTL15	psi-mi:“MI:0914”(association)	0.530

BioGRID (156): EXOC6 (Affinity Capture-MS), EXOC6 (Affinity Capture-MS), EXOC6 (Affinity Capture-MS), EXOC6 (Affinity Capture-MS), EXOC6 (Co-fractionation), EXOC6 (Co-fractionation), EXOC6 (Co-fractionation), EXOC6 (Co-fractionation), EXOC6 (Co-fractionation), EXOC8 (Co-fractionation), NAE1 (Co-fractionation), EXOC6 (Affinity Capture-MS), EXOC6 (Affinity Capture-MS), EXOC6 (Affinity Capture-Western), EXOC6 (Affinity Capture-Western)

ESM2 similar proteins: A2A432, A6H5Z3, A9X1D0, B0VX69, B1MTJ4, B2KI88, B5FW36, C1FXW2, E2R766, E2RBS6, F1LSG8, O43242, O54923, O55047, O70133, P60762, Q13098, Q13619, Q13620, Q29425, Q2KJ46, Q3TCH7, Q4V860, Q5NVP9, Q5R5J4, Q5RAN1, Q5RB36, Q5VIR6, Q5ZKV9, Q5ZLD7, Q5ZML9, Q6AYU1, Q6NRT5, Q6NZH6, Q86TU7, Q8CCB4, Q8CI71, Q8K4Q0, Q8N122, Q8R3S6

Diamond homologs: A6H5Z3, E2R766, O54923, Q18286, Q8R313, Q8TAG9, Q9VDE6, Q9Y2D4

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
EXOC6	“form complex”	“Exocyst_EXOC6 variant”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 125 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
VxPx cargo-targeting to cilium	8	48.3×	1e-09
Insulin processing	7	37.2×	1e-07
Translocation of SLC2A4 (GLUT4) to the plasma membrane	8	14.4×	1e-05

GO biological processes:

GO term	Partners	Fold	FDR
obsolete vesicle docking involved in exocytosis	9	55.7×	1e-11
Golgi to plasma membrane transport	6	30.9×	5e-06
membrane fission	8	30.2×	5e-08
mitotic cytokinesis	8	19.0×	1e-06
exocytosis	10	13.9×	5e-07

Disease & clinical

Clinical variants and AI predictions

ClinVar

115 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	78
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

5263 predictions. Top by Δscore:

Variant	Effect	Δscore
10:92867211:A:G	donor_gain	1.0000
10:92893347:A:G	acceptor_loss	1.0000
10:92893348:GGTCT:G	acceptor_gain	1.0000
10:92893517:GAAG:G	donor_gain	1.0000
10:92893518:AAGG:A	donor_loss	1.0000
10:92893520:GGT:G	donor_loss	1.0000
10:92893521:G:C	donor_loss	1.0000
10:92893521:G:GG	donor_gain	1.0000
10:92893522:T:G	donor_loss	1.0000
10:92894927:A:AG	acceptor_gain	1.0000
10:92894927:AAG:A	acceptor_gain	1.0000
10:92894927:AAGGT:A	acceptor_gain	1.0000
10:92894928:A:G	acceptor_gain	1.0000
10:92895017:CCTGG:C	donor_loss	1.0000
10:92895018:CTGG:C	donor_loss	1.0000
10:92895019:TGG:T	donor_loss	1.0000
10:92895020:GGTGA:G	donor_loss	1.0000
10:92895021:G:T	donor_loss	1.0000
10:92895022:TGA:T	donor_loss	1.0000
10:92895023:GAG:G	donor_loss	1.0000
10:92899597:A:AG	acceptor_gain	1.0000
10:92899598:G:GA	acceptor_gain	1.0000
10:92909421:TCACA:T	acceptor_loss	1.0000
10:92909582:A:T	donor_gain	1.0000
10:92909632:GT:G	donor_loss	1.0000
10:92909633:T:A	donor_loss	1.0000
10:92915913:GGTGA:G	donor_gain	1.0000
10:92928335:TTAG:T	acceptor_loss	1.0000
10:92928336:TAG:T	acceptor_loss	1.0000
10:92928337:A:AG	acceptor_gain	1.0000

AlphaMissense

5385 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:92928379:G:C	R310T	1.000
10:92928380:A:C	R310S	1.000
10:92928380:A:T	R310S	1.000
10:92955611:T:C	L557P	1.000
10:92974186:T:C	L636P	1.000
10:93056934:T:C	L727P	1.000
10:93056951:T:A	W733R	1.000
10:93056951:T:C	W733R	1.000
10:92893486:T:C	L80P	0.999
10:92909575:T:C	F203L	0.999
10:92909577:T:A	F203L	0.999
10:92909577:T:G	F203L	0.999
10:92909612:G:A	G215D	0.999
10:92928379:G:T	R310I	0.999
10:92928390:G:C	A314P	0.999
10:92928397:T:C	L316P	0.999
10:92934189:G:T	G340W	0.999
10:92934190:G:A	G340E	0.999
10:92934311:T:C	F341L	0.999
10:92934313:C:A	F341L	0.999
10:92934313:C:G	F341L	0.999
10:92940797:T:C	L428P	0.999
10:92952301:C:T	S482F	0.999
10:92952360:T:C	F502L	0.999
10:92952362:T:A	F502L	0.999
10:92952362:T:G	F502L	0.999
10:92954657:A:C	R518S	0.999
10:92954657:A:T	R518S	0.999
10:92954677:T:C	L525P	0.999
10:92955600:C:A	N553K	0.999

dbSNP variants (sampled 300 via entrez): RS1000008465 (10:93032918 A>G), RS1000018395 (10:92858325 T>A,C), RS1000032412 (10:92913071 A>G,T), RS1000038098 (10:93038427 A>G), RS1000038172 (10:92856508 TTC>T), RS1000065549 (10:92993362 C>T), RS1000074344 (10:92856750 C>T), RS1000078370 (10:93054900 C>T), RS1000087859 (10:92864333 G>A), RS1000095825 (10:92899166 G>A), RS1000101169 (10:92964035 A>G), RS1000126531 (10:92999577 G>A), RS1000127508 (10:93016874 G>A), RS1000135712 (10:92841048 C>CT), RS1000153819 (10:92873716 A>G,T)

Disease associations

OMIM: gene MIM:609672 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): breast ductal adenocarcinoma (MONDO:0005590)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

18 associations (top):

Study	Trait	p-value
GCST004904_161	Body mass index	3.000000e-12
GCST004904_51	Body mass index	2.000000e-09
GCST005160_2	Insulin levels in response to oral glucose tolerance test (30 minutes)	5.000000e-07
GCST005194_196	Coronary artery disease	4.000000e-06
GCST005407_1	Glaucoma (primary open-angle)	2.000000e-06
GCST005980_20	Total bilirubin levels	1.000000e-09
GCST006001_27	Hemoglobin A1c levels	2.000000e-11
GCST006005_6	High density lipoprotein cholesterol levels	1.000000e-10
GCST006394_73	Intraocular pressure	8.000000e-12
GCST007876_115	Estimated glomerular filtration rate	1.000000e-09
GCST009440_8	Age-related cognitive decline (attention/processing speed) (slope of z-scores)	7.000000e-06
GCST009602_86	Metabolic syndrome	4.000000e-08
GCST010002_297	Refractive error	3.000000e-23
GCST010796_3318	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-08
GCST011348_23	High density lipoprotein cholesterol levels	2.000000e-10
GCST012442_14	Age-related hearing impairment	5.000000e-10
GCST90002382_195	Eosinophil percentage of white cells	2.000000e-13
GCST90002401_217	Platelet distribution width	8.000000e-12

EFO canonical traits (12, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0004307	glucose tolerance test
EFO:0004467	insulin measurement
EFO:0004570	bilirubin measurement
EFO:0004541	HbA1c measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0004695	intraocular pressure measurement
EFO:0007710	cognitive decline measurement
EFO:0000195	metabolic syndrome
EFO:0004327	electrocardiography
EFO:0007991	eosinophil percentage of leukocytes
EFO:0007984	platelet component distribution width

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
trichostatin A	affects cotreatment, decreases expression	3
Benzo(a)pyrene	decreases expression	3
sodium arsenite	decreases expression, increases abundance	2
Arsenic	affects methylation, decreases expression, increases abundance	2
Aflatoxin B1	decreases expression, decreases methylation	2
aristolochic acid I	decreases expression	1
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	increases methylation	1
cobaltous chloride	decreases expression	1
manganese chloride	decreases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
nickel sulfate	decreases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	decreases expression	1
incobotulinumtoxinA	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Temozolomide	increases expression	1
Cisplatin	decreases expression	1
Dimethyl Sulfoxide	increases expression	1
Doxorubicin	decreases expression	1
Estradiol	affects cotreatment, decreases expression	1
Formaldehyde	decreases expression	1
Lead	affects expression	1
Manganese	decreases expression	1

Clinical trials (associated diseases)

11 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03414970	PHASE3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT00461344	PHASE2	TERMINATED	Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT07499999	PHASE2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT00637364	PHASE1/PHASE2	SUSPENDED	High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
NCT02779855	PHASE1/PHASE2	COMPLETED	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01753908	EARLY_PHASE1	COMPLETED	Broccoli Sprout Extract in Treating Patients With Breast Cancer
NCT01796041	EARLY_PHASE1	COMPLETED	Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01208974	Not specified	ACTIVE_NOT_RECRUITING	Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
NCT01875198	Not specified	TERMINATED	Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
NCT03543397	Not specified	UNKNOWN	MRI in Ductal Carcinoma in Situ (DCIS)
NCT03834532	Not specified	COMPLETED	Living Well After Breast Surgery